Ruti Aga's Six-Year Ban: When a Fake Prescription Outweighed the Banned Substance

On 10 September, a 32-year-old marathoner was struck from every start list for six years. The sanction, issued by the Athletics Integrity Unit (AIU) — World Athletics' independent integrity body — was assembled from two parts: two years for the presence of methylprednisolone in a sample, four years for tampering with the evidence during results management. The heavier half was reserved for the paperwork, not the vial. Nine years of tracking road races and spreadsheets have taught me that doping sanctions are usually quantified in nanograms per millilitre, in elimination half-lives, in laboratory margins of error. This time the entire weight of the case rested on an old prescription pad, a clinic that does not exist, and a signature from a family member. None of that is measurable. It still has to be written down, because that is where the data actually lives. Who is Ruti Aga in the distance-running landscape? She won the 2026 Tokyo Marathon and finished runner-up at World Marathon Majors three times — the circuit comprising Tokyo, Boston, London, Berlin, Chicago and New York. At 32 she sat at the top of the performance window, which for female marathoners commonly extends to 35 and beyond. The ban landed at her point of maximum competitive and commercial value, not during a decline. The triggering event was a half marathon in China in March. That detail matters structurally. For more than a decade, Chinese road races have operated as a large demand market, drawing hundreds of Ethiopian and Kenyan athletes with appearance fees — income far from trivial against living costs in the high-altitude camps of East Africa. Those races generally carry lighter testing density than the majors, a mismatch between prize level and scrutiny. For Aga, everything began with a knee injury. She stated she took medication to treat it. This is where every model I can build has to stop: the source gives no route of administration, no injection date, no elimination timeline in her body. Without those three variables, any inference about intent is guesswork. One technical correction is needed. Several reports describe methylprednisolone as a “steroid”. It is more precisely a synthetic glucocorticoid — a corticosteroid, an anti-inflammatory class. It sits in WADA class S9, prohibited in-competition only, and is a Specified Substance. Those three properties reshape the entire framework: S9 is not banned out of competition; Specified Substances are recognised as more plausibly linked to inadvertent or therapeutic use; and the baseline sanction is two years, reducible sharply where intent cannot be shown. Put simply, on the substance side Aga stood on the softer half of the scale. The other half was not soft at all. The AIU found that the prescription Aga submitted during results management came from a clinic that does not exist. The signatory was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace; the workplace confirmed in writing that she had never worked there. The named clinic also confirmed the prescription was not theirs. The evidentiary chain closed at all four ends. The medical facility denied it. The prescription pad was traced. The registration did not exist. The family relationship was established. Under the WADA Code, tampering during results management is an independent violation with its own penalty, and multiple violations are served consecutively rather than concurrently. That is why two plus four became six, rather than the maximum of four. A shift in verification practice deserves note. The AIU now routinely calls clinics directly, checks professional registration and cross-references staff lists. Detecting a forged prescription takes weeks, not months. The expected cost of fabricating documents has risen sharply while the benefit sits at zero. That kind of change never shows up in a spreadsheet, yet it shapes human behaviour more than any stated sanction. I rebuilt the scenario table for this case. Had a valid TUE covered the knee treatment, and had the route of administration fallen outside the in-competition window, the most plausible outcome was no violation at all, or a reduced sanction. Had she disclosed a therapeutic error honestly, the penalty could have stopped at a year or less. What actually happened: six years, the March result annulled, prize money forfeited, major invitations gone, and a return to the top at 38 essentially impossible. Across those three scenarios, the decisive variable was not the molecule. It was the paper. The financial damage deserves separate treatment. A world-class marathoner does not earn a salary. Income arrives through appearance fees, placement bonuses, shoe contracts and invitation slots. A six-year ban erases all four streams at once, and does so irreversibly: a 38-year-old returning after six years away is no longer a name organisers pay to invite. At national level the effect is close to zero. Ethiopia's development pipeline is deep enough that losing one major-calibre athlete leaves no gap in national output. Kenya is the same. The two nations have shared almost the entire leading group of women's marathon running for years, and every vacated slot is filled immediately. Aga was a replaceable node. For her, this is the end of a career. For the sport, it is a footnote. The counter-intuitive angle sits elsewhere. Public reaction will read the case as a doping story and conclude the severity is justified because cheating occurred. Split the two halves apart and the structure points at a different weakness: the legal and medical support system surrounding East African road runners. Compare resources. A footballer in a top European league has personal lawyers, a communications department and a club-run TUE process. An Ethiopian marathoner earning hundreds of thousands of dollars a season in appearance fees often handles her own paperwork, and when a crisis arrives the adviser is a relative at the kitchen table. The result of that gap is not sophisticated cover-ups. It is clumsy ones — and the clumsiness is precisely why they are caught quickly. At Russia 2026 I watched data shatter in front of me. The lesson was this: when people decide under missing information and time pressure, a model explains what already happened, never what will happen next. The Aga case belongs to that family. A relative sitting in front of a blank prescription pad, under pressure to save a 32-year-old's career, chose the worst option by expected value. No model predicts that choice. The post-hoc data records it perfectly. That leads to a caution about reading evidence. I do not have enough cases to say what this reveals about the Ethiopian system. A single incident, executed by one athlete and one relative, cannot establish a systemic problem — just as one failed forecast cannot invalidate a model. The temptation to generalise is strong, because “fake doctor in the family” is a far better headline than “an individual administrative error”. Data does not manufacture stories; it strips the stories of others bare. And the story stripped bare here belongs to a small group of people, not to a nation. The limits of this analysis need stating plainly. The source gives no date for the March half marathon, no finishing time, no route of administration for methylprednisolone, no year. Those four gaps prevent me from attaching any probability to the “valid TUE” scenario. I can say the scenario existed. I cannot say how likely it was. A data monk has to distinguish between those two sentences. The signal worth tracking next sits with organisers, not athletes. Chinese road races have a commercial incentive to tighten medical verification for invited runners. The Ethiopian federation has an incentive to build TUE guidance into junior athlete education. And the AIU, with a tampering finding now on record, has grounds to review stored samples. Every probability carries a shock inside it — I only make sure it does not repeat. What deserves thought is the hierarchy the system has now set: an athlete who used a corticosteroid to treat a knee was punished three times as heavily as the act of using that substance. Is the sport protecting the cleanliness of the race, or the cleanliness of the file?